A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

This clinical trial aims to characterize the safety of OL-101 and establish the recommended dose for future research and to evaluate the efficacy of OL-101 (Dose expansion).

Trial Details

NCT ID
NCT06644118
Phase
PHASE1
Sponsor
Zhejiang University
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • OL-101 infusion
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Xi’an, Shanxi, China|35.99785,113.52486
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Documented diagnosis of multiple myeloma according to the 2014 IMWG diagnostic criteria
  • Relapsed/refractory multiple myeloma as defined by:
  • 1\) Received at least 3 prior lines of MM treatment (must include a PI, an IMiD, and an anti-CD38 antibody).
  • 2）Disease progression within 12 months of the most recent anti-MM therapy; or disease progression within the past 6 months and subsequently lack re…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →